Heteroaryl compounds as btk inhibitors and uses thereof
US-2016264548-A1 · Sep 15, 2016 · US
US10012650B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10012650-B2 |
| Application number | US-201514964945-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 10, 2015 |
| Priority date | Dec 11, 2014 |
| Publication date | Jul 3, 2018 |
| Grant date | Jul 3, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to BTK occupancy assays.
Opening claim text (preview).
We claim: 1. A method for determining drug target occupancy of a BTK inhibitor compound, comprising: (a) contacting a sample comprising a mixture of BTK kinase and a BTK inhibitor compound, with a probe to form a probe-bound kinase; (b) detecting the amount of probe-bound kinase in the sample; and (c) determining the occupancy of the BTK inhibitor compound based on the amount of probe-bound kinase detected in the sample; wherein the probe is: 2. The method of claim 1 , wherein the step of determining target occupancy comprises determining the number of binding sites not occupied by the BTK kinase inhibitor based on the amount of probe-bound kinase detected in the sample. 3. The method of claim 1 , further comprising a step of determining or modifying a therapeutic regimen based on the target occupancy of the BTK kinase. 4. The method of claim 1 , further comprising a step of performing the method at two or more time points.
involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title
Immunoassay; Biospecific binding assay; Materials therefor · CPC title
involving labelled substances (G01N33/53 takes precedence) · CPC title
Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor) · CPC title
transferring phosphorus containing groups, e.g. kinases (2.7) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.